Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04390243 · ClinicalTrials.gov registry record · Phase 2
Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation
A Phase 2 study, sponsored by Academic and Community Cancer Research United.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04390243: Clinical Trial Phase 2 study, sponsored by Academic and Community Cancer Research United.
NCT04390243 is a Phase 2 study that was terminated before completion, run by Academic and Community Cancer Research United. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04390243, a Phase 2 study, was terminated before completion, sponsored by Academic and Community Cancer Research United.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects and how well the combination of binimetinib and encorafenib work in treating patients with pancreatic cancer with a somatic BRAF V600E mutation. Binimetinib and encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and encorafenib may work better compared to the usual treatment in treating patients with pancreatic cancer and a somatic BRAF V600E mutation.
Primary Outcome
An objective response is defined as a complete or partial response with a confirmation scan not less than 4 weeks after the initial scan. Disease status will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria. The final ORR point estimate and corresponding 95% confidence interval will be reported.
Interventions
- DRUG Binimetinib
- DRUG Encorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-11-16 |
| Est. Completion | 2023-11-01 |
| Phase | Phase 2 |
Why NCT04390243 stopped before completion
NCT04390243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Binimetinib is the first listed.
NCT04390243 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04390243 about?
NCT04390243 is a clinical study titled "Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation". This phase II trial studies the side effects and how well the combination of binimetinib and encorafenib work in treating patients with pancreatic cancer with a somatic BRAF V600E mutation. Binimetinib and encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell...
What is the current status of trial NCT04390243?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2020-11-16. Estimated completion is 2023-11-01.
What interventions are being tested in trial NCT04390243?
The interventions under investigation include: Binimetinib (DRUG), Encorafenib (DRUG).
Who is sponsoring clinical trial NCT04390243?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04390243's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI